HEMGENIX®
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Key Publications
Publications
Gene therapy with etranacogene dezaparvovec for hemophilia B
Pipe SW, Leebeek FWG, Recht M, et al. N Engl J Med. 2023Request | Ask a Question | View Article
Posters
Etranacogene dezaparvovec-drlb hemophilia B gene therapy Phase 2b trial final results: Stable and durable FIX level expression over 5 years
Please see full prescribing information for HEMGENIX
IX-TEND: A Phase IV Observational, Long-term Follow-up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B
Please see full prescribing information for HEMGENIX
First Real-world Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B
Please see full prescribing information for HEMGENIX
Sustained efficacy and safety 3 years following infusion with etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B in the Phase 3 HOPE-B clinical trial
Please see full prescribing information for HEMGENIX
HIV Comorbid Infection and Liver-Directed AAV-Based Gene Therapy in Adults with Severe and Moderately Severe Hemophilia B: Efficacy and Safety Results from Phase 2b and the Pivotal Phase 3 HOPE-B Trials 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec
Please see full prescribing information for HEMGENIX
Adult Patients With Hemophilia B and With a History of Chronic HCV/HBV Infection Receiving Liver Directed Gene Therapy Demonstrated Long-Term Bleeding Protection And Sustained FIX Activity: Efficacy and Safety Results 3 Years After Administration of a Single Dose of Etranacogene Dezaparvovec
Please see full prescribing information for HEMGENIX
Stable and durable factor IX levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B
Please see full prescribing information for HEMGENIX
Management of Infusion Reactions: Lessons from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B
Please see full prescribing information for HEMGENIX
Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals With and Without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) With Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
Please see full prescribing information for HEMGENIX
Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy
Please see full prescribing information for HEMGENIX
Analysis of elevated alanine transaminase in HOPE B, a Phase 3 recombinant adeno associated viral 5 gene therapy trial in people with haemophilia B
Please see full prescribing information for HEMGENIX
Durability of Factor IX Activity and Bleeding Rate in People With Severe or Moderately Severe Hemophilia B After 5 Years of Follow-Up in the Phase 1/2 Study of AMT-060, and After 3 Years of Follow-Up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)
Please see full prescribing information for HEMGENIX
